Dextromoramide

Identification

Name
Dextromoramide
Accession Number
DB01529
Type
Small Molecule
Groups
Experimental, Illicit
Description

An opioid analgesic structurally related to methadone and used in the treatment of severe pain. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1070)

Structure
Thumb
Synonyms
  • (+)-1-(3-methyl-4-morpholino-2,2-diphenylbutyryl)pyrrolidine
  • (+)-4-(2-methyl-4-oxo-3,3-diphenyl-4-(1-pyrrolidinyl)butyl)morpholine
  • 1-((3S)-3-methyl-4-(4-morpholinyl)-1-oxo-2,2-diphenylbutyl)pyrrolidine
  • 4-(2-methyl-4-oxo-3,3-diphenyl-4-(1-pyrrolidinyl)butyl)morpholine
  • D-2,2-diphenyl-3-methyl-4-morpholinobutyrylpyrrolidine
  • dextromoramida
  • dextromoramidum
  • palphium
  • Pyrrolamidol
External IDs
ACSCN-9613 / IDS-ND-003 / MCP-875 / R-875 / SKF-5137
International/Other Brands
palfium
Categories
UNII
9S4S6CIY83
CAS number
357-56-2
Weight
Average: 392.543
Monoisotopic: 392.246378278
Chemical Formula
C25H32N2O2
InChI Key
INUNXTSAACVKJS-OAQYLSRUSA-N
InChI
InChI=1S/C25H32N2O2/c1-21(20-26-16-18-29-19-17-26)25(22-10-4-2-5-11-22,23-12-6-3-7-13-23)24(28)27-14-8-9-15-27/h2-7,10-13,21H,8-9,14-20H2,1H3/t21-/m1/s1
IUPAC Name
(3S)-3-methyl-4-(morpholin-4-yl)-2,2-diphenyl-1-(pyrrolidin-1-yl)butan-1-one
SMILES
C[[email protected]](CN1CCOCC1)C(C(=O)N1CCCC1)(C1=CC=CC=C1)C1=CC=CC=C1

Pharmacology

Indication
Not Available
Structured Indications
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
2,5-Dimethoxy-4-ethylamphetamine2,5-Dimethoxy-4-ethylamphetamine may increase the analgesic activities of Dextromoramide.Experimental, Illicit
3,4-Methylenedioxyamphetamine3,4-Methylenedioxyamphetamine may increase the analgesic activities of Dextromoramide.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamine4-Bromo-2,5-dimethoxyamphetamine may increase the analgesic activities of Dextromoramide.Experimental, Illicit
7-NitroindazoleThe risk or severity of adverse effects can be increased when Dextromoramide is combined with 7-Nitroindazole.Experimental
7,8-Dichloro-1,2,3,4-tetrahydroisoquinolineThe risk or severity of adverse effects can be increased when Dextromoramide is combined with 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline.Experimental
AcepromazineThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Acepromazine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Aceprometazine.Approved
AcetazolamideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Acetazolamide.Approved, Vet Approved
AclidiniumThe risk or severity of adverse effects can be increased when Aclidinium is combined with Dextromoramide.Approved
AdipiplonThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Adipiplon.Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Agomelatine.Approved, Investigational
AlaproclateDextromoramide may increase the serotonergic activities of Alaproclate.Experimental
AlcuroniumThe risk or severity of adverse effects can be increased when Alcuronium is combined with Dextromoramide.Experimental
AlfaxaloneThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Alfaxalone.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Dextromoramide.Approved, Illicit
AlimemazineAlimemazine may increase the hypotensive activities of Dextromoramide.Approved, Vet Approved
AllopregnanoloneThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Allopregnanolone.Investigational
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Alphacetylmethadol.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Alphaprodine.Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Dextromoramide.Approved, Illicit, Investigational
AlvimopanThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Alvimopan.Approved
AmilorideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Amiloride.Approved
AmisulprideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Amisulpride.Approved, Investigational
AmitriptylineThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Amitriptyline.Approved
Ammonium chlorideAmmonium chloride may increase the excretion rate of Dextromoramide which could result in a lower serum level and potentially a reduction in efficacy.Approved, Vet Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Dextromoramide.Approved, Illicit
AmoxapineThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Amoxapine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Amperozide.Experimental
AmphetamineAmphetamine may increase the analgesic activities of Dextromoramide.Approved, Illicit
Anisotropine MethylbromideThe risk or severity of adverse effects can be increased when Anisotropine Methylbromide is combined with Dextromoramide.Approved
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Dextromoramide.Approved, Investigational
ArticaineThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Articaine.Approved
AsenapineThe risk or severity of adverse effects can be increased when Asenapine is combined with Dextromoramide.Approved
AtracuriumThe risk or severity of adverse effects can be increased when Atracurium is combined with Dextromoramide.Experimental
Atracurium besylateThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Dextromoramide.Approved
AtropineThe risk or severity of adverse effects can be increased when Atropine is combined with Dextromoramide.Approved, Vet Approved
AzaperoneThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Azaperone.Vet Approved
AzelastineDextromoramide may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
AzosemideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Azosemide.Investigational
BaclofenThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Baclofen.Approved
BarbitalThe risk or severity of adverse effects can be increased when Barbital is combined with Dextromoramide.Illicit
BenactyzineThe risk or severity of adverse effects can be increased when Benactyzine is combined with Dextromoramide.Withdrawn
BendroflumethiazideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Bendroflumethiazide.Approved
BenmoxinThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Benmoxin.Withdrawn
BenperidolThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Benperidol.Investigational
BenzatropineThe risk or severity of adverse effects can be increased when Benzatropine is combined with Dextromoramide.Approved
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Dextromoramide.Approved
BenzphetamineBenzphetamine may increase the analgesic activities of Dextromoramide.Approved, Illicit
Benzyl alcoholThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Benzyl alcohol.Approved
BiperidenThe risk or severity of adverse effects can be increased when Biperiden is combined with Dextromoramide.Approved
BL-1020BL-1020 may increase the hypotensive activities of Dextromoramide.Investigational
BornaprineThe risk or severity of adverse effects can be increased when Bornaprine is combined with Dextromoramide.Experimental
BrexpiprazoleThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Brexpiprazole.Approved
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Dextromoramide.Approved
BrofaromineThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Brofaromine.Experimental
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Dextromoramide.Approved, Illicit
BromisovalThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Bromisoval.Experimental
BromperidolThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Bromperidol.Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Brompheniramine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Brotizolam.Approved, Withdrawn
BumetanideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Bumetanide.Approved
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Dextromoramide.Approved, Investigational
BuprenorphineDextromoramide may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Dextromoramide.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Dextromoramide.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Butacaine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Butalbital.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Butamben.Approved
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Dextromoramide.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Dextromoramide.Approved, Illicit, Vet Approved
CanertinibThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Canertinib.Investigational
Canrenoic acidThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Canrenoic acid.Approved, Withdrawn
CanrenoneThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Canrenone.Investigational
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Dextromoramide.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Carbinoxamine.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Carfentanil.Illicit, Vet Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Carisoprodol.Approved
CaroxazoneThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Caroxazone.Withdrawn
CetirizineThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Cetirizine.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Chloral hydrate.Approved, Illicit, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Dextromoramide.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Dextromoramide.Approved, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Dextromoramide.Approved
ChlorothiazideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Chlorothiazide.Approved, Vet Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Chlorphenamine.Approved
ChlorphenoxamineThe risk or severity of adverse effects can be increased when Chlorphenoxamine is combined with Dextromoramide.Withdrawn
ChlorphentermineChlorphentermine may increase the analgesic activities of Dextromoramide.Illicit, Withdrawn
ChlorproethazineChlorproethazine may increase the hypotensive activities of Dextromoramide.Experimental
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Dextromoramide.Approved, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Dextromoramide.Approved, Withdrawn
ChlorthalidoneThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Chlorthalidone.Approved
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Chlorzoxazone.Approved
CicletanineThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Cicletanine.Investigational
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Dextromoramide.Approved, Vet Approved
CitalopramDextromoramide may increase the serotonergic activities of Citalopram.Approved
ClemastineThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Clemastine.Approved
ClidiniumThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Clidinium.Approved
ClobazamThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Clobazam.Approved, Illicit
ClofenamideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Clofenamide.Experimental
clomethiazoleThe risk or severity of adverse effects can be increased when Dextromoramide is combined with clomethiazole.Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Clomipramine.Approved, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Clonazepam.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Clonidine.Approved
ClopamideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Clopamide.Experimental
ClopenthixolThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Clopenthixol.Experimental
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Dextromoramide.Approved, Illicit
ClorexoloneThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Clorexolone.Experimental
ClothiapineThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Clothiapine.Experimental
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Dextromoramide.Approved
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Dextromoramide.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Dextromoramide.Approved, Illicit
ConivaptanThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Conivaptan.Approved, Investigational
CyclizineThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Cyclizine.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Dextromoramide.Approved
CyclopenthiazideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Cyclopenthiazide.Experimental
CyclopentolateThe risk or severity of adverse effects can be increased when Cyclopentolate is combined with Dextromoramide.Approved
CyclothiazideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Cyclothiazide.Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Cyproheptadine.Approved
DantroleneThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Dantrolene.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Dextromoramide.Approved
DapoxetineDextromoramide may increase the serotonergic activities of Dapoxetine.Investigational
DarifenacinThe risk or severity of adverse effects can be increased when Darifenacin is combined with Dextromoramide.Approved, Investigational
DeramciclaneThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Deramciclane.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Dextromoramide.Approved
DesipramineThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Desipramine.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Desloratadine.Approved, Investigational
DesmopressinThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Desmopressin.Approved
DesvenlafaxineDextromoramide may increase the serotonergic activities of Desvenlafaxine.Approved
DetomidineThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Detomidine.Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Dexbrompheniramine.Approved
DexetimideThe risk or severity of adverse effects can be increased when Dexetimide is combined with Dextromoramide.Withdrawn
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Dextromoramide.Approved, Vet Approved
DextroamphetamineDextroamphetamine may increase the analgesic activities of Dextromoramide.Approved, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Dextromoramide.Approved, Illicit, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Dextromoramide.Approved
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Dextromoramide.Approved, Illicit, Vet Approved
DicyclomineThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Dextromoramide.Approved
Diethyl etherThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Diethyl ether.Experimental
DiethylpropionDiethylpropion may increase the analgesic activities of Dextromoramide.Approved, Illicit
DifenoxinThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Difenoxin.Approved, Illicit
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Dextromoramide.Approved, Illicit
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Dextromoramide.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Dihydromorphine.Experimental, Illicit
DimenhydrinateThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Dimenhydrinate.Approved
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Dextromoramide.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Dextromoramide.Approved, Illicit
DixyrazineThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Dixyrazine.Experimental
DoramectinThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Doramectin.Vet Approved
DoxepinThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Doxepin.Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Dextromoramide.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when Dextromoramide is combined with DPDPE.Investigational
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Dextromoramide.Approved, Illicit
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Dextromoramide.Approved, Vet Approved
DrospirenoneThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Drospirenone.Approved
DrotebanolThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Drotebanol.Experimental, Illicit
DuloxetineDextromoramide may increase the serotonergic activities of Duloxetine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Dextromoramide.Approved
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Dextromoramide.Experimental, Illicit
EcopipamThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Ecopipam.Investigational
EfavirenzThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Efavirenz.Approved, Investigational
EfonidipineThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Efonidipine.Approved
EltanoloneThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Eltanolone.Investigational
EluxadolineDextromoramide may increase the constipating activities of Eluxadoline.Approved
EmeproniumThe risk or severity of adverse effects can be increased when Emepronium is combined with Dextromoramide.Experimental
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Dextromoramide.Approved, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Entacapone.Approved, Investigational
EplerenoneThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Eplerenone.Approved
EscitalopramDextromoramide may increase the serotonergic activities of Escitalopram.Approved, Investigational
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Dextromoramide.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Dextromoramide.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Etacrynic acid.Approved
EtanautineThe risk or severity of adverse effects can be increased when Etanautine is combined with Dextromoramide.Experimental
EthanolDextromoramide may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Dextromoramide.Approved, Illicit, Withdrawn
EthopropazineThe risk or severity of adverse effects can be increased when Ethopropazine is combined with Dextromoramide.Approved
EthosuximideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Ethosuximide.Approved
EthotoinThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Ethotoin.Approved
EthoxzolamideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Ethoxzolamide.Withdrawn
Ethyl carbamateThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Ethyl carbamate.Withdrawn
Ethyl chlorideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Ethyl chloride.Experimental
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Ethyl loflazepate.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Dextromoramide.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Etidocaine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Etifoxine.Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Etizolam.Approved
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Dextromoramide.Approved
EtoperidoneDextromoramide may increase the serotonergic activities of Etoperidone.Approved
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Dextromoramide.Illicit, Vet Approved
EtybenzatropineThe risk or severity of adverse effects can be increased when Etybenzatropine is combined with Dextromoramide.Experimental
EzogabineThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Ezogabine.Approved
FelbamateThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Felbamate.Approved
FencamfamineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Dextromoramide.Approved, Illicit, Withdrawn
FenquizoneThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Fenquizone.Experimental
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Dextromoramide.Approved, Illicit, Investigational, Vet Approved
FesoterodineThe risk or severity of adverse effects can be increased when Fesoterodine is combined with Dextromoramide.Approved
FexofenadineThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Fexofenadine.Approved
FlibanserinThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Flibanserin.Approved
FluanisoneThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Fluanisone.Experimental
FludiazepamThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Fludiazepam.Approved, Illicit
FlunarizineThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Flunarizine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Flunitrazepam.Approved, Illicit
FluoxetineDextromoramide may increase the serotonergic activities of Fluoxetine.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Dextromoramide.Approved, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Dextromoramide.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Dextromoramide.Approved, Illicit
FluspirileneThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Fluspirilene.Approved
Fluticasone propionateThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Fluticasone propionate.Approved
FluvoxamineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Dextromoramide.Approved, Investigational
FosphenytoinThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Fosphenytoin.Approved
FospropofolThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Fospropofol.Approved, Illicit
FurazolidoneThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Furazolidone.Approved, Vet Approved
FurosemideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Furosemide.Approved, Vet Approved
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Dextromoramide.Approved, Investigational
Gabapentin EnacarbilThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Gabapentin Enacarbil.Approved
GallamineThe risk or severity of adverse effects can be increased when Gallamine is combined with Dextromoramide.Experimental
Gallamine TriethiodideThe risk or severity of adverse effects can be increased when Gallamine Triethiodide is combined with Dextromoramide.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Dextromoramide.Approved, Illicit
GepefrineGepefrine may increase the analgesic activities of Dextromoramide.Experimental
GepironeThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Gepirone.Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with Dextromoramide.Approved, Illicit
GlycopyrroniumThe risk or severity of adverse effects can be increased when Glycopyrronium is combined with Dextromoramide.Approved, Investigational, Vet Approved
GuanfacineThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Guanfacine.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Dextromoramide.Approved, Illicit, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Dextromoramide.Approved
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Dextromoramide.Approved, Vet Approved
HarmalineThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Harmaline.Experimental
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Dextromoramide.Approved, Illicit
HexamethoniumThe risk or severity of adverse effects can be increased when Hexamethonium is combined with Dextromoramide.Experimental
HexobarbitalThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Dextromoramide.Approved
HomatropineThe risk or severity of adverse effects can be increased when Homatropine is combined with Dextromoramide.Approved
HydracarbazineThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Hydracarbazine.Experimental
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Hydrochlorothiazide.Approved, Vet Approved
HydrocodoneDextromoramide may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydroflumethiazideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Hydroflumethiazide.Approved
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Dextromoramide.Approved, Illicit
HydroxyamphetamineHydroxyamphetamine may increase the analgesic activities of Dextromoramide.Approved
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Dextromoramide.Approved
HyoscyamineThe risk or severity of adverse effects can be increased when Hyoscyamine is combined with Dextromoramide.Approved
IbopamineThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Ibopamine.Experimental
IloperidoneThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Iloperidone.Approved
ImipramineThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Imipramine.Approved
IndalpineDextromoramide may increase the serotonergic activities of Indalpine.Investigational, Withdrawn
IndapamideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Indapamide.Approved
IndiplonThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Indiplon.Investigational
Iofetamine I-123Iofetamine I-123 may increase the analgesic activities of Dextromoramide.Approved
Ipratropium bromideThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Dextromoramide.Approved
IproclozideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Iproclozide.Withdrawn
IproniazidThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Iproniazid.Withdrawn
IsocarboxazidThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Isocarboxazid.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Dextromoramide.Approved, Vet Approved
IsosorbideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Isosorbide.Approved
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Dextromoramide.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Ketazolam.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Ketobemidone.Approved
LamotrigineThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Lamotrigine.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Levetiracetam.Approved, Investigational
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Dextromoramide.Approved
LevocabastineThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Levocabastine.Approved
LevocetirizineThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Levocetirizine.Approved
LevodopaThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Levodopa.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Dextromoramide.Approved
LevomilnacipranDextromoramide may increase the serotonergic activities of Levomilnacipran.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Dextromoramide.Approved
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Dextromoramide.Approved, Vet Approved
LisdexamfetamineLisdexamfetamine may increase the analgesic activities of Dextromoramide.Approved, Investigational
LithiumThe risk or severity of adverse effects can be increased when Lithium is combined with Dextromoramide.Approved
LofentanilThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Lofentanil.Illicit
LoprazolamThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Loprazolam.Experimental
LoratadineThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Loratadine.Approved
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Dextromoramide.Approved
LormetazepamThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Lormetazepam.Approved
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Dextromoramide.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Dextromoramide.Approved
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Dextromoramide.Approved, Vet Approved
MannitolThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Mannitol.Approved, Investigational
MaprotilineThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Maprotiline.Approved
MazaticolThe risk or severity of adverse effects can be increased when Mazaticol is combined with Dextromoramide.Experimental
MebanazineThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Mebanazine.Withdrawn
MebicarThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Mebicar.Experimental
MebutizideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Mebutizide.Experimental
MecamylamineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Dextromoramide.Approved
MeclizineThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Meclizine.Approved
MedazepamThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Medazepam.Experimental
MedetomidineThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Medetomidine.Vet Approved
MefrusideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Mefruside.Experimental
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Dextromoramide.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Melperone.Approved
MephedroneMephedrone may increase the analgesic activities of Dextromoramide.Investigational
MephentermineMephentermine may increase the analgesic activities of Dextromoramide.Approved
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Dextromoramide.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Dextromoramide.Approved, Illicit
MeptazinolThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Meptazinol.Experimental
MersalylThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Mersalyl.Approved
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Dextromoramide.Approved
MetaxaloneThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Metaxalone.Approved
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Dextromoramide.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Dextromoramide.Approved, Illicit
MethamphetamineMethamphetamine may increase the analgesic activities of Dextromoramide.Approved, Illicit
MethanthelineThe risk or severity of adverse effects can be increased when Methantheline is combined with Dextromoramide.Approved
MethapyrileneThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Methapyrilene.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Methaqualone.Illicit, Withdrawn
MethazolamideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Methazolamide.Approved
MethocarbamolThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Methocarbamol.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Dextromoramide.Approved
MethotrimeprazineDextromoramide may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Dextromoramide.Approved, Vet Approved
MethoxyphenamineMethoxyphenamine may increase the analgesic activities of Dextromoramide.Experimental
MethsuximideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Methsuximide.Approved
MethyclothiazideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Methyclothiazide.Approved
MethylecgonineThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Methylecgonine.Experimental
Methylene blueMethylene blue may increase the hypotensive activities of Dextromoramide.Investigational
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Dextromoramide.Approved
MeticraneThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Meticrane.Experimental
MetixeneThe risk or severity of adverse effects can be increased when Metixene is combined with Dextromoramide.Approved
MetolazoneThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Metolazone.Approved
MetyrosineDextromoramide may increase the sedative activities of Metyrosine.Approved
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Dextromoramide.Approved, Illicit
Midomafetamine3,4-Methylenedioxymethamphetamine may increase the analgesic activities of Dextromoramide.Experimental, Illicit
MilnacipranDextromoramide may increase the serotonergic activities of Milnacipran.Approved
MinaprineThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Minaprine.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Dextromoramide.Approved, Investigational
MirtazapineDextromoramide may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MMDAMMDA may increase the analgesic activities of Dextromoramide.Experimental, Illicit
MoclobemideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Moclobemide.Approved
MolindoneThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Molindone.Approved
MoricizineMoricizine may increase the hypotensive activities of Dextromoramide.Approved, Withdrawn
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Dextromoramide.Approved, Investigational
MuzolimineThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Muzolimine.Experimental
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Dextromoramide.Approved, Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Dextromoramide.Approved
NaltrexoneThe therapeutic efficacy of Dextromoramide can be decreased when used in combination with Naltrexone.Approved, Investigational, Vet Approved
NefazodoneDextromoramide may increase the serotonergic activities of Nefazodone.Approved, Withdrawn
NialamideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Nialamide.Withdrawn
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Dextromoramide.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Dextromoramide.Approved, Vet Approved
NorfluraneThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Norflurane.Investigational
NormethadoneThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Normethadone.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Nortriptyline.Approved
OctamoxinThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Octamoxin.Withdrawn
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Dextromoramide.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Olopatadine.Approved
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Dextromoramide.Approved
OpiumThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Opium.Approved, Illicit
OrphenadrineDextromoramide may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Osanetant.Investigational
OtiloniumThe risk or severity of adverse effects can be increased when Otilonium is combined with Dextromoramide.Experimental
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Dextromoramide.Approved
OxethazaineThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Oxethazaine.Investigational
OxitropiumThe risk or severity of adverse effects can be increased when Oxitropium is combined with Dextromoramide.Investigational
OxprenololThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Oxprenolol.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Dextromoramide.Approved
OxybutyninThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Dextromoramide.Approved, Investigational
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Dextromoramide.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Dextromoramide.Approved, Investigational, Vet Approved
OxyphenoniumThe risk or severity of adverse effects can be increased when Oxyphenonium is combined with Dextromoramide.Approved
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Dextromoramide.Approved
PancuroniumThe risk or severity of adverse effects can be increased when Pancuronium is combined with Dextromoramide.Approved
ParaldehydeDextromoramide may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved
PargylineThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Pargyline.Approved
ParoxetineDextromoramide may increase the serotonergic activities of Paroxetine.Approved, Investigational
PegvisomantThe therapeutic efficacy of Pegvisomant can be decreased when used in combination with Dextromoramide.Approved
PenfluridolThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Penfluridol.Experimental
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Dextromoramide.Approved, Vet Approved
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Dextromoramide.Approved, Vet Approved
PentoliniumThe risk or severity of adverse effects can be increased when Pentolinium is combined with Dextromoramide.Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Dextromoramide.Approved
PerazineThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Perazine.Investigational
PerospironeThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Perospirone.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Dextromoramide.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Dextromoramide.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Phenazocine.Experimental
PhenelzineThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Phenelzine.Approved
PhenglutarimideThe risk or severity of adverse effects can be increased when Phenglutarimide is combined with Dextromoramide.Experimental
PhenibutThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Phenibut.Experimental
PheniprazineThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Pheniprazine.Withdrawn
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Dextromoramide.Approved
PhenoperidineThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Phenoperidine.Experimental
PhenoxyethanolThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Phenoxyethanol.Approved
PhenoxypropazineThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Phenoxypropazine.Withdrawn
PhenterminePhentermine may increase the analgesic activities of Dextromoramide.Approved, Illicit
PhenytoinThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Phenytoin.Approved, Vet Approved
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Dextromoramide.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Pipamperone.Approved
PipecuroniumThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Dextromoramide.Approved
PipotiazineThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Pipotiazine.Approved
PirenzepineThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Dextromoramide.Approved
PiretanideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Piretanide.Experimental
PiritramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Piritramide.Investigational
PirlindoleThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Pirlindole.Approved
PivhydrazineThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Pivhydrazine.Withdrawn
PizotifenThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Pizotifen.Approved
PolythiazideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Polythiazide.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Pomalidomide.Approved
PotassiumThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Potassium.Approved
Potassium CitrateThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Potassium Citrate.Approved, Vet Approved
PramipexoleDextromoramide may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Pramocaine.Approved
PrazepamThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Prazepam.Approved, Illicit
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Dextromoramide.Approved, Illicit, Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Dextromoramide.Approved
PrimidoneThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Primidone.Approved, Vet Approved
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Dextromoramide.Approved, Investigational, Vet Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Dextromoramide.Approved, Vet Approved
ProcyclidineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Dextromoramide.Approved
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Dextromoramide.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Promethazine.Approved
PropanididThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Propanidid.Experimental
PropanthelineThe risk or severity of adverse effects can be increased when Propantheline is combined with Dextromoramide.Approved
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Dextromoramide.Approved, Vet Approved
PropiopromazinePropiopromazine may increase the hypotensive activities of Dextromoramide.Vet Approved
PropiverineThe risk or severity of adverse effects can be increased when Propiverine is combined with Dextromoramide.Investigational
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Dextromoramide.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Propoxycaine.Approved
ProtriptylineThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Protriptyline.Approved
ProxibarbalThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Proxibarbal.Experimental
PSD502The risk or severity of adverse effects can be increased when Dextromoramide is combined with PSD502.Investigational
PseudoephedrinePseudoephedrine may increase the analgesic activities of Dextromoramide.Approved
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Dextromoramide.Approved, Illicit
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Dextromoramide.Approved
QuinethazoneThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Quinethazone.Approved
QuinidineThe risk or severity of adverse effects can be increased when Quinidine is combined with Dextromoramide.Approved
QuinisocaineThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Quinisocaine.Experimental
RacloprideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Raclopride.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Ramelteon.Approved, Investigational
RamosetronDextromoramide may increase the constipating activities of Ramosetron.Approved
RasagilineThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Rasagiline.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Dextromoramide.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Dextromoramide.Approved, Withdrawn
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Dextromoramide.Approved
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Dextromoramide.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Ritanserin.Investigational
RitobegronRitobegron may increase the analgesic activities of Dextromoramide.Investigational
RolofyllineThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Rolofylline.Investigational
RomifidineThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Romifidine.Vet Approved
RopiniroleDextromoramide may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Dextromoramide.Approved
RotigotineDextromoramide may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Dextromoramide.Approved
SafrazineThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Safrazine.Withdrawn
ScopolamineThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Scopolamine.Approved
Scopolamine butylbromideThe risk or severity of adverse effects can be increased when Scopolamine butylbromide is combined with Dextromoramide.Approved, Vet Approved
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Dextromoramide.Approved, Vet Approved
SelegilineThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Selegiline.Approved, Investigational, Vet Approved
SepranoloneThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Sepranolone.Investigational
SertindoleThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Sertindole.Approved, Withdrawn
SertralineDextromoramide may increase the serotonergic activities of Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Dextromoramide.Approved, Vet Approved
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Dextromoramide.Approved
SolifenacinThe risk or severity of adverse effects can be increased when Solifenacin is combined with Dextromoramide.Approved
SpiradolineThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Spiradoline.Investigational
SpironolactoneThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Spironolactone.Approved
StiripentolThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Stiripentol.Approved
SuccinylcholineSuccinylcholine may increase the bradycardic activities of Dextromoramide.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Dextromoramide.Approved, Investigational
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Dextromoramide.Approved
SultoprideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Sultopride.Experimental
SuvorexantDextromoramide may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
TandospironeThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Dextromoramide.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Tasimelteon.Approved
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Dextromoramide.Approved
TetrabenazineThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Tetrabenazine.Approved
TetracaineThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Tetracaine.Approved, Vet Approved
TetrahydropalmatineThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Tetrahydropalmatine.Investigational
TetrodotoxinThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Tetrodotoxin.Investigational
ThalidomideDextromoramide may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
TheobromineThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Theobromine.Approved
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Dextromoramide.Approved, Vet Approved
ThiazinamThiazinam may increase the hypotensive activities of Dextromoramide.Experimental
ThiethylperazineThiethylperazine may increase the hypotensive activities of Dextromoramide.Withdrawn
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Dextromoramide.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Dextromoramide.Withdrawn
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Dextromoramide.Approved
TiagabineThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Tiagabine.Approved
TiaprideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Tiapride.Approved, Investigational
TicrynafenThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Ticrynafen.Withdrawn
TiletamineThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Tiletamine.Vet Approved
TilidineThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Tilidine.Experimental
TiotropiumThe risk or severity of adverse effects can be increased when Tiotropium is combined with Dextromoramide.Approved
TizanidineThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Tizanidine.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Tolcapone.Approved, Withdrawn
ToloxatoneThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Toloxatone.Approved
TolterodineThe risk or severity of adverse effects can be increased when Tolterodine is combined with Dextromoramide.Approved, Investigational
TolvaptanThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Tolvaptan.Approved
TopiramateThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Topiramate.Approved
TorasemideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Torasemide.Approved
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Dextromoramide.Approved, Investigational
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Trans-2-Phenylcyclopropylamine.Experimental
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Dextromoramide.Approved
TrazodoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Dextromoramide.Approved, Investigational
TriamtereneThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Triamterene.Approved
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Dextromoramide.Approved
Tricaine methanesulfonateThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Tricaine methanesulfonate.Vet Approved
TrichlormethiazideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Trichlormethiazide.Approved, Vet Approved
TrichloroethyleneThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Trichloroethylene.Experimental
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Dextromoramide.Approved
TrifluperidolThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Trifluperidol.Experimental
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Dextromoramide.Approved, Vet Approved
TrihexyphenidylThe risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Dextromoramide.Approved
TrimethaphanThe risk or severity of adverse effects can be increased when Trimethaphan is combined with Dextromoramide.Approved
TrimipramineThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Trimipramine.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Triprolidine.Approved
TropatepineThe risk or severity of adverse effects can be increased when Tropatepine is combined with Dextromoramide.Experimental
TropicamideThe risk or severity of adverse effects can be increased when Tropicamide is combined with Dextromoramide.Approved
TrospiumThe risk or severity of adverse effects can be increased when Trospium is combined with Dextromoramide.Approved
TubocurarineThe risk or severity of adverse effects can be increased when Tubocurarine is combined with Dextromoramide.Approved
UlaritideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Ularitide.Investigational
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Dextromoramide.Approved, Investigational
VecuroniumThe risk or severity of adverse effects can be increased when Vecuronium is combined with Dextromoramide.Approved
VenlafaxineDextromoramide may increase the serotonergic activities of Venlafaxine.Approved
VeraliprideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Veralipride.Experimental
VigabatrinThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Vigabatrin.Approved
Vinyl etherThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Vinyl ether.Experimental
VortioxetineThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Vortioxetine.Approved
XenonThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Xenon.Experimental
XipamideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Xipamide.Experimental
XylazineThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Xylazine.Vet Approved
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Dextromoramide.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Ziconotide.Approved
ZimelidineDextromoramide may increase the serotonergic activities of Zimelidine.Withdrawn
ZiprasidoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Dextromoramide.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Zolazepam.Vet Approved
ZolpidemDextromoramide may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Zonisamide.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Dextromoramide.Approved
ZotepineThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Zotepine.Approved
ZuclopenthixolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Dextromoramide.Approved, Investigational
Food Interactions
Not Available

References

Synthesis Reference
Not Available
General References
Not Available
External Links
KEGG Drug
D07287
ChemSpider
83901
ChEBI
74274
ChEMBL
CHEMBL2365707
Wikipedia
Dextromoramide
ATC Codes
N02AC01 — Dextromoramide
AHFS Codes
Not Available
PDB Entries
Not Available
FDA label
Not Available
MSDS
Not Available

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)182 °CPhysProp
logP3.61SANGSTER (1994)
Predicted Properties
PropertyValueSource
Water Solubility0.0175 mg/mLALOGPS
logP4.17ALOGPS
logP3.75ChemAxon
logS-4.4ALOGPS
pKa (Strongest Basic)7.77ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area32.78 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity117.37 m3·mol-1ChemAxon
Polarizability44.36 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9941
Blood Brain Barrier+0.986
Caco-2 permeable+0.5628
P-glycoprotein substrateSubstrate0.6229
P-glycoprotein inhibitor IInhibitor0.6781
P-glycoprotein inhibitor IINon-inhibitor0.573
Renal organic cation transporterInhibitor0.525
CYP450 2C9 substrateNon-substrate0.8056
CYP450 2D6 substrateNon-substrate0.7581
CYP450 3A4 substrateSubstrate0.6149
CYP450 1A2 substrateNon-inhibitor0.9177
CYP450 2C9 inhibitorNon-inhibitor0.9297
CYP450 2D6 inhibitorInhibitor0.5
CYP450 2C19 inhibitorNon-inhibitor0.6691
CYP450 3A4 inhibitorNon-inhibitor0.6655
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.7777
Ames testNon AMES toxic0.801
CarcinogenicityNon-carcinogens0.919
BiodegradationNot ready biodegradable0.9549
Rat acute toxicity3.7072 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8914
hERG inhibition (predictor II)Non-inhibitor0.6829
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as diphenylmethanes. These are compounds containing a diphenylmethane moiety, which consists of a methane wherein two hydrogen atoms are replaced by two phenyl groups.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Diphenylmethanes
Direct Parent
Diphenylmethanes
Alternative Parents
Phenylacetamides / Phenylpropanes / N-acylpyrrolidines / Aralkylamines / Morpholines / Tertiary carboxylic acid amides / Trialkylamines / Amino acids and derivatives / Oxacyclic compounds / Dialkyl ethers
show 4 more
Substituents
Diphenylmethane / Phenylacetamide / Phenylpropane / N-acylpyrrolidine / Aralkylamine / Morpholine / Oxazinane / Tertiary carboxylic acid amide / Pyrrolidine / Amino acid or derivatives
show 18 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
N-acylpyrrolidine, morpholines (CHEBI:74274 )

Drug created on July 31, 2007 07:10 / Updated on October 02, 2017 04:59